For a short explanation of why the committee made this recommendation for research, see the rationale section on treatment strategies for non-proliferative and proliferative diabetic retinopathy .

Full details of the evidence and the committee's discussion are in evidence review A: prognostic factors for progression of non-proliferative diabetic retinopathy.

EyePoint Pharmaceuticals, Inc.’s EYPT share price has dipped by 15.13%, which has investors questioning if this is right time to buy.

and findings from a clinical trial focused on non-proliferative diabetic retinopathy. Ocular is utilizing its proprietary bioresorbable hydrogel technology, ELUTYX™, in its ongoing trials ...

outlined exceptional clinical progress across its registrational program for AXPAXLI™ in wet age-related macular degeneration (wet AMD), plans to advance AXPAXLI in non-proliferative diabetic ...

Ocular Therapeutix (OCUL) plans to advance AXPAXLI in non-proliferative diabetic retinopathy, NPDR, and the Company’s strategic outlook for 2025 in its presentation at the 43rd Annual J.P ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

DR was graded according to early Treatment Diabetic Retinopathy (ETDRS ... (70.35%), which included 34 patients (17.1%) with mild non proliferative DR (NPDR), 34 patients (17.1%) with moderate ...

James analyst Dane Leone maintained a Strong Buy rating and a $19.00 price target on Ocular Therapeutix (NASDAQ:OCUL), aligning with the broader analyst consensus. According to InvestingPro data, ...

which evaluated the treatment in patients with moderately severe to severe non-proliferative diabetic retinopathy. Leveraging the GLOW1 study's success, Kodiak initiated the GLOW2 study in late ...